ASTEX PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2011-01-01

Employees: 136

Market Cap: -

Website: http://www.astx.com

Clinical Trials

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Phase 1

Completed

Conditions: MDS
CMML
AML

Interventions: Drug: SGI-110

First Posted Date: 2010-12-16

Last Posted Date: 2021-04-20

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 401

Registration Number: NCT01261312

Locations: 🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Florida Cancer Specialists - North, Saint Petersburg, Florida, United States

and more 13 locations

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Phase 1

Withdrawn

Conditions: Relapsed/Refractory Leukemias

First Posted Date: 2010-11-11

Last Posted Date: 2024-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Registration Number: NCT01239108

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: AT7519M
Drug: Bortezomib

First Posted Date: 2010-08-18

Last Posted Date: 2024-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 18

Registration Number: NCT01183949

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Faber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

Phase 1

Completed

Conditions: Solid Tumors

First Posted Date: 2009-05-07

Last Posted Date: 2024-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 22

Registration Number: NCT00894894

Locations: 🇺🇸
Translation Genomics Research Institute (TGen)/Scottsdale Clin.Researc, Scottsdale, Arizona, United States
🇺🇸
So. Texas Accelerated Research Therapeutics-START, San Antonio, Texas, United States

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Phase 1

Completed

Conditions: Malignant Disease

Interventions: Drug: MP-470 + paclitaxel/carboplatin
Drug: MP-470 + carboplatin/etoposide
Drug: MP-470 + topotecan
Drug: MP-470 + docetaxel
Drug: MP-470 + erlotinib

First Posted Date: 2009-04-15

Last Posted Date: 2024-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 101

Registration Number: NCT00881166

Locations: 🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸
Audie Murphy Veterans Memorial Hospital (VA), San Antonio, Texas, United States
🇺🇸
CTRC at the UT Health Science Center at San Antonio, San Antonio, Texas, United States

and more 1 locations

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Phase 1

Completed

Conditions: Metastatic Solid Tumors

First Posted Date: 2009-04-09

Last Posted Date: 2024-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 62

Registration Number: NCT00878423

Locations: 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Prostate Cancer
Non-Hodgkins Lymphoma

First Posted Date: 2009-02-20

Last Posted Date: 2024-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 14

Registration Number: NCT00848601

Locations: 🇬🇧
Royal Marsden Hospital, Sutton, England, United Kingdom
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Cancer Therapy Research Center, San Antonio, Texas, United States

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Phase 1

Terminated

Conditions: Myelofibrosis
Chronic Myeloid Leukemia
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: AT9283

First Posted Date: 2007-08-30

Last Posted Date: 2024-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 48

Registration Number: NCT00522990

Locations: 🇺🇸
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

Not Applicable

Terminated

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2007-07-19

Last Posted Date: 2013-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT00504205

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea, Scottsdale, Arizona, United States

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

First Posted Date: 2005-06-07

Last Posted Date: 2024-08-02

Lead Sponsor: Astex Pharmaceuticals, Inc.

Target Recruit Count: 39

Registration Number: NCT00113256

Locations: 🇺🇸
Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸
Medical Oncology, Baton Rouge, Louisiana, United States
🇺🇸
N. Mississippi Hematology & Oncology Associates, Tupelo, Mississippi, United States

and more 8 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy